TuisIONS • BMV
add
Ionis Pharmaceuticals Inc
Vorige sluiting
$900,00
Jaarwisseling
$737,51 - $900,00
Markkapitalisasie
5,45 mjd USD
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 119,50 m | -8,45% |
Bedryfskoste | 52,64 m | 15,66% |
Netto inkomste | -142,80 m | -14,86% |
Netto winsgrens | -119,50 | -25,46% |
Wins per aandeel | -0,77 | -13,09% |
EBITDA | -146,33 m | -31,90% |
Effektiewe belastingkoers | -0,05% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,21 mjd | -5,93% |
Totale bates | 2,76 mjd | -4,20% |
Totale aanspreeklikheid | 2,47 mjd | 2,87% |
Totale ekwiteit | 296,52 m | — |
Uitstaande aandele | 145,97 m | — |
Prys om te bespreek | 443,35 | — |
Opbrengs op bates | -12,99% | — |
Opbrengs op kapitaal | -16,15% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -142,80 m | -14,86% |
Kontant van bedrywe | -149,94 m | -11,90% |
Kontant van beleggings | 76,10 m | 123,37% |
Kontant van finansiering | 23,57 m | -95,21% |
Netto kontantverandering | -50,38 m | -254,73% |
Beskikbare kontantvloei | -92,63 m | 3,45% |
Meer oor
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Gestig
1989
Hoofkwartier
Webwerf
Werknemers
927
